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CC BY license (http:
http://dx.doi.org/10Inherited gene variants play an important role in malignant diseases. The transcriptional
repressor growth factor independence 1 (GFI1) regulates hematopoietic stem cell (HSC)
self-renewal and differentiation. A single-nucleotide polymorphism of GFI1 (rs34631763)
generates a protein with an asparagine (N) instead of a serine (S) at position 36
(GFI136N) and has a prevalence of 3%–5% among Caucasians. Because GFI1 regulates
myeloid development, we examined the role of GFI136N on the course of MDS disease. To
this end, we determined allele frequencies of GFI136N in four independent MDS cohorts
from the Netherlands and Belgium, Germany, the ICGC consortium, and the United States.
The GFI136N allele frequency in the 723 MDS patients genotyped ranged between 9% and
12%. GFI136N was an independent adverse prognostic factor for overall survival, acute
myeloid leukemia-free survival, and event-free survival in a univariate analysis. After
adjustment for age, bone marrow blast percentage, IPSS score, mutational status, and cyto-
genetic findings, GFI136N remained an independent adverse prognostic marker. GFI136S
homozygous patients exhibited a sustained response to treatment with hypomethylating
agents, whereas GFI136N patients had a poor sustained response to this therapy. Because
allele status of GFI136N is readily determined using basic molecular techniques, we propose
inclusion of GFI136N status in future prospective studies for MDS patients to better predict
prognosis and guide therapeutic decisions. Copyright  2016 ISEH - International Society
for Experimental Hematology. Published by Elsevier Inc. This is an open access article un-
der the CC BY license (http://creativecommons.org/licenses/by/4.0/)., and CK contributed equally to this work.
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related to this article can be found online at http://
exphem.2016.04.001.
 2016 ISEH - International Society for Experimental Hem
//creativecommons.org/licenses/by/4.0/).
.1016/j.exphem.2016.04.001GFI1 is a zinc finger transcriptional repressor that recruits
histone-modifying enzymes, such as histone deacetylases,
to the loci of its target genes [1,2]. GFI1 regulates the
functions of hematopoietic stem cells (HSCs) [1,3] as
well as myeloid–lymphoid lineage decisions [4,5]. A
variant form of the GFI1 gene (denominated GFI136N)atology. Published by Elsevier Inc. This is an open access article under the
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acute myeloid leukemia (AML) [6], but it has also been
reported to be involved in a case of neutropenia [7].
Taking into consideration the predisposing role of
GFI136N to de novo AML and its role in myeloid develop-
ment, we investigated the role of GFI136N in myelodys-
plastic syndrome (MDS).
Methods
Patient cohort
All patient samples (peripheral blood [PB] or bone marrow [BM]
aspirates) were obtained with informed consent according to the
Declaration of Helsinki. The respective local ethics committees
approved the use of all patient samples.
The clinical characteristics of patients with a confirmed diag-
nosis of MDS used in this study have been previously described
[8–13]. Events in ‘‘event-free survival’’ were defined as death
from any cause or progression of MDS to AML with blast counts
higher than 20%. Overall survival events are defined as death from
any cause.
Bone marrow morphology and cytopenia classification
Bone marrow morphology studies were performed at individual
centers. MDS was classified based on the World Health Organiza-
tion (WHO) definition [14].
Genotyping
Genotyping was performed according to published procedures [6].
Statistical methods
Significance of differences in percentages was determined using
the two-sided, two-sample t test. Survival of the different human
cohorts is based on the presence of GFI136N univariate analysis us-
ing Kaplan–Meier survival methods. Differences were assessed
using the log-rank (Mantel–Cox) test. We used Cox
proportional-hazards regression modeling to determine the influ-
ence of different factors with respect to survival. Factors taken
into account were International Prognostic Scoring System
(IPSS) risk group, BM blast count, age, sex, cytogenetic findings
(based on IPSS classification), and in a last step, presence of
GFI136N. Analyses were performed either separately (with each
factor analyzed independently) or with the presence or absence
of GFI136N. All p values reported are two-sided. Because of the
exploratory nature of this study, no adjustment for multiple testing
was done. All analyses presented were performed using GraphPad
Prism 6 software (GraphPad Software, La Jolla, CA) or SPSS
Version 19 (IBM, Armonk, NY).
Results
Between 9% and 12% of all adult MDS patients in four
different Caucasian cohorts from Europe and the United
States [8–12] were heterozygous for GFI136N, and only
two patients from the European cohorts (and none of
the U.S. cohort) were homozygous for GFI136N
(Table 1). GFI136N allele frequency was higher among
MDS patients than among the control cohort (3%–5%)
as reported in our previous study regarding the role of
GFI136N in de novo AML [15]. Although we did notdetermine the frequency of GFI136N among sex- and
age-matched control subjects from every region, it is
possible that GFI136N predisposes to MDS, similar to its
predisposing role in de novo AML [15].
We analyzed the effect of GFI136N onMDS disease course
in two independent cohorts. Patients were recruited and
treated either in the United States or in Europe. The European
cohorts consisted of patients recruited and treated at different
centers in Germany, Belgium, and The Netherlands [8–12].
The U.S. cohorts were referred to the Cleveland Clinic.
In the two MDS cohorts from Europe and the United
States, presence of GFI136N was associated with an inferior
event-free survival rate (Fig. 1A, B). GFI136N also had a
negative impact on overall survival (Fig. 1C, D) and on
AML-free survival (data not shown).
Next, we examined the association between GFI136N
and established prognostic factors. GFI136N carriers were
older, exhibited a tendency toward higher BM blast counts
at diagnosis, were diagnosed with a more advanced stage
of the disease according to histologic parameters, and
had more adverse cytogenetic findings (Table 1). With
respect to key blood parameters, no other differences be-
tween GFI136N and GFI136S carriers were observed
(Table 1).
American and European GFI136S homozygous patients
had median follow-ups of 1,100 and 975 days, respectively.
American and European GFI136N carriers had median
follow-ups of 540 and 350 days, respectively. To gain
more statistical power and to perform more specific anal-
ysis, we combined the U.S. and European cohorts. One
approach used to predict outcome of MDS patients is based
on IPSS [16,17]. A recently introduced, revised version of
IPSS (denominated IPSS-R) distinguishes between more
subclasses based on cytogenetic findings and cytopenic lin-
eages [16]. However, not all of the specific data for deter-
mining IPSS-R status were present in our databases.
Therefore, we focused our examination on the nonrevised
version of IPSS.
As reported previously [17], IPSS scoring predicted
event-free outcome of GFI136S homozygous patients
(Fig. 1E). On the basis of the same scoring system,
GFI136N carriers had a significantly shorter event-free sur-
vival (Fig. 1F). Especially among MDS patients in the
low-risk groups (groups low and intermediate 1 based on
IPSS), GFI136N carriers had a much shorter event-free
(Fig. 1G) and AML-free survival (data not shown) than
GFI136S homozygous patients. We also examined the asso-
ciation between allele status, cytogenetic findings and
event-free survival. Similarly, presence of GFI136N was
associated with an inferior outcome, independent of the cy-
togenetic finding (Table 1). After stratification for cytoge-
netic risk groups (‘‘low’’ as one group and ‘‘intermediate
and high’’ as a second group), the presence of a GFI136N
allele was again linked to inferior event-free survival
(Fig. 1H, I) in both comparisons.
Table 1. Features of GFI136N- and GFI136S-carrying adult MDS
patientsa
GFI136N (homo
[2 patients]- or
heterozygous)
GFI136S
(homozygozus) P value
% All countries 10 (n 5 75) 90 (n 5 648)
% United States 11 (n 5 30) 89 (n 5 254)
% Germany 9 (n 5 20) 91 (n 5 193)
% Netherlands
and Belgium
12 (n 5 11) 88 (n 5 84)
% ICGC 11 (n 5 14) 89 (n 5 117)
Mean age 66 6 1.5 (n 5 73) 62 6 0.6 (n 5 638) 0.01
Gender (% male) 64 (n 5 47) 66 (n 5 426) 0.7
Blast percentage
(BM) WHO
9.4 6 0.3 (n 5 48) 6.7 6 1.1 (n 5 464) 0.01
Hemoglobin
(mg/dL)
8.4 6 0.5 (n 5 24) 8.1 6 0.1 (n 5 191) 0.57
Platelet count
(1/nL)
186 6 37 (n 5 24) 177 6 11 (n 5 195) 0.8
Neutrophil count
(1/nL)
2.8 6 0.8 (n 5 24) 2.7 6 0.2 (n 5 196) 0.9
Cytogenetic low
risk (%)
46 (n 5 27) 62 (n 5 246) 0.03
Cytogenetic
intermediate
risk (%)
14 (n 5 8) 16 (n 5 64) 0.5
Cytogenetic high
risk (%)
41 (n 5 24) 24 (n 5 96) 0.006
IPSS low (%) 25 (n 5 13) 25 (n 5 127) 0.7
IPSS intermediate
1 (%)
40 (n 5 38) 42 (n 5 323) 0.7
IPSS intermediate
2 (%)
21 (n 5 11) 21 (n 5 109) 0.7
IPSS high (%) 15 (n 5 8) 10 (n 5 52) 0.25
5q– (%) 5 (n 5 2) 4 (n 5 13) 0.8
RA (%) 0 (n 5 0) 9 (n 5 30) 0.054
RARSþ RARST
(%)
11 (n 5 4) 9 (n 5 28) 0.7
RAEB-1 (%) 22 (n 5 8) 18 (n 5 59) 0.65
RAEB-2 (%) 39 (n 5 15) 22 (n 5 69) 0.02
RAEB-1 þ
RAEB-2 (%)
61 (23) 40 (128) 0.01
RCMD (%) 24 (n 5 9) 38 (n 5 123) 0.09
MDS-u (%) 0 1 (n 5 4) 0.5
BM 5 bone marrow; ICGC 5 International Cancer Genome Consortium;
WHO 5 World Health Organization.
aGFI136N includes patients who are either homozygous or heterozygous
for GFI136N and, thus, carrying one GFI136S allele. GFI136S refers to pa-
tients homozygous for GFI136S. Cytogenetic low risk: normal karyotype,
5q–, 20q–, –Y; poor risk: complex aberrations ($3 anomalies), chromo-
some 7 anomalies; intermediate risk: all other aberrations. IPSS was
based on Greenberg et al. [17]. Refractory anemia (RA), refractory
anemia with ring sideroblasts (RARS), refractory anemia with excess
blasts, type 1 (RAEB-1), refractory anemia with excess blasts, type 2
(RAEB-2), refractory cytopenia with multilineage dysplasia (RCMD),
and MDS-unclassified (MDS-u) are based on the WHO definition for
MDS. Standard errors of mean are given. Data for IPPS and cytogenetic
classification are missing due to the lack of cytogenetic information on
patients at the time of diagnosis. Data for histologic classification are
missing because of the missing specification of MDS according to
WHO criteria. The missing patients were diagnosed as having MDS ac-
cording to the WHO definition. Student’s t test was used to determine the
significance of values, and two-sample t tests were used to determine the
=
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ASXL1 have an inferior prognosis [18,19] (Fig. 2A, B).
Presence of GFI136N in the absence of ASXL1 or EZH2
mutations had a similar effect on event-free survival as
the presence of ASXL1 or EZH2 mutations (Fig. 2C,
D). Furthermore, the combined presence of a mutated
form of either ASXL1 or EZH2 and a GFI136N allele
had an additional adverse effect on event-free survival
(Fig. 2C, D). Similar analyses were not possible for muta-
tions of P53 or RUNX1 [18,19], because of the small
number of cases with P53 or RUNX1 mutation and
GFI136N.
Because MDS patients who are hetero- or homozygous
for GFI136N tend to be older at diagnosis, have more
frequent adverse cytogenetic findings, and have a higher
blast cell count at diagnosis, we examined whether the pres-
ence of GFI136N represents an adverse prognostic factor af-
ter adjusting for these findings. We found that GFI136N was
an independent marker after adjusting for the variables
IPSS score, cytogenetic findings, and age, either alone or
in combination (Supplementary Tables E1 and E2, online
only, available at www.exphem.org).Discussion
One possible explanation why GFI136N accelerates AML
development in MDS patients could be based on our find-
ings using murine models. We previously generated mice
expressing GFI136N or GFI136S instead of murine Gfi1
[15]. We reported that GFI136N is not able to bind to its
target genes to the same extent as the more common
‘‘wild-type’’ GFI136S variant. Hence, presence of one
allele of GFI136N led to higher genomewide levels of
acetylated histone 3 at lysine 9 (H3K9) at Gfi1 target
genes. This led to active expression of genes favoring
development of myeloid malignancies [15], which could
explain how GFI136N accelerates both AML development
and MDS–AML progression. We recently reported that a
low level of GFI1 expression, which might mimic the
presence of GFI136N on a functional level, accelerates
AML progression in different murine models of AML,
including one model of MDS [20]. It is not yet clear
why altering one amino acid changes the function of
GFI1, and initial experiments regarding expression level,
stability, ability to induce apoptosis, or interaction with
histone deacetylases (HDACs) or lysine-specific deme-
thylase 1 (LSD1) did not reveal any significant differ-
ences between GFI136N and GFI136S [15] (unpublished
data).significance of differences between percentages. The different cohorts
were independent of each other. No overlap exists with respect to sam-
ples. The numbers in parentheses correspond to the absolute numbers
related to the indicated percentages.
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Figure 1. Correlation between GFI136N and disease course of patients with MDS. (A) Patients from different European cohorts diagnosed with MDS on the
basis of WHO criteria were genotyped with respect to the presence of GFI136N and examined with respect to median event-free survival (see also Methods);
95% confidence interval (CI) 5 1.6–5.6. Median survival is indicated. (B) MDS Patients from a U.S. cohort diagnosed with MDS on the basis of WHO
criteria were genotyped with respect to the presence of GFI136N and examined with respect to median event-free survival; 95% CI5 1.7–7.2. Median survival
is indicated. (C) The same cohorts as in (A) were examined with respect to overall survival (death of any cause); 95% CI 5 1.0–3.9. Median survival is
indicated. (D) The same cohort as in (B) was examined with respect to overall survival (death from any cause) 95% CI 5 1.5–5.8. Median survival is indi-
cated. (E) Event-free survival of GFI136S homozygous patients was stratified based on IPSS classification. No sufficient follow-up was available for the In-
ternational Cancer Genome Consortium (ICGC) patients. Follow-up is based on the patient cohorts from the United States, the Netherlands, Belgium, and
Germany. Median survival is indicated. (F) Event-free survival of GFI136N homozygous or heterozygous patients was stratified based on IPSS classification.
No sufficient follow up was available for the ICGC patients. Follow-up is based on the patient cohorts from the United States, the Netherlands, Belgium, and
Germany. Median survival is indicated. (G) Event-free survival of patients (shown in A) classified as either IPSS subtype low or intermediate 1 (int-1) was
stratified with respect to the presence of GFI136N; 95% CI 5 1.4–6.2. (H) Patients from the U.S. and European cohorts with cytogenetic risk characteristics
belonging to subtype ‘‘low’’ were stratified by the presence of GFI136N with respect to event-free survival; 95% CI 5 1.5–5.7. Median survival is indicated.
(I) Patients from the U.S. and European cohorts with cytogenetic risk characteristics belonging to subtype ‘‘intermediate’’ or ‘‘high’’ were stratified by pres-
ence of GFI136N with respect to event-free survival; 95% CI 5 3.3–23.3. Median survival is indicated.
593L. Botezatu et al./ Experimental Hematology 2016;44:590–595We also examined whether GFI136N could predict
response to therapy. To explore this in more detail, we
focused on patients that were treated with 5-azacitidine.
This treatment is used for patients who are otherwise notfit for allogeneic bone marrow transplantation or as a
bridging to a definitive therapy [21–23]. There was no dif-
ference between GFI136N heterozygous carriers and
GFI136S patients achieving response to treatment with
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Figure 2. Association between GFI136N, mutational status, prognosis, and therapeutic response. (A) Median event-free survival of patients based on muta-
tional status of ASXL1; 95% confidence interval (CI) 5 1.5–5.7. (B) Median event-free survival of patients based on mutational status of EZH2; 95%
CI 5 3.4–23.3. (C) Median event-free survival of patients based on presence of GFI136N and mutational status of ASXL1. (D) Median event-free survival
of patients based on presence of GFI136N and mutational status of EZH2. (E) From the cohorts of patients treated in Europe and the United States, patients
treated with 5-azacitidine were stratified with respect to GFI1 status. Presence of GFI136N was associated with a shorter response. Median survival is indi-
cated; 95% CI 5 1.1–10.5.
594 L. Botezatu et al./ Experimental Hematology 2016;44:590–5955-azacytidine (51% of GFI136S homozygous carriers
compared with 52% of GFI136N carriers). However, the
response to treatment was much shorter in GFI136N carriers
than in GFI136S homozygous carriers (Fig. 2E). This obser-
vation is not surprising because treatment with hypomethy-
lating agents, such as 5-azacitidine, would not revert the
increased levels of H3K9 acetylation and H3K4 methyl-
ation seen in cells with a GFI136N allele [15].The suitability of GFI136N as a prognostic marker should
be verified in prospective studies and, if the findings can be
confirmed, the status of GFI136N should be determined
routinely in MDS patients. Considering the role of GFI1 in
myeloid development, GFI136N status could also be of prog-
nostic value for patients with myeloproliferative diseases and
chronic myeloid leukemia. Indeed, the frequency of GFI136N
is also elevated among patients with chronic myeloid
595L. Botezatu et al./ Experimental Hematology 2016;44:590–595leukemia. In summary, GFI136N could be a useful therapeu-
tic and prognostic marker for myeloid malignancies.Acknowledgments
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Supplementary Table E1. Cox survival regression adjusted for IPSSa
Variable Wald c2 p value
Hazard
ratio
95% CI for
hazard ratio
Lower Upper
IPSS 77.381 0.000
IPSS low 13.699 0.000 0.504 0.350 0.724
IPSS intermediate 1 4.607 0.032 0.725 0.540 0.972
IPSS intermediate 2 1.586 0.208 1.229 0.892 1.694
IPSS high 32.297 0.000 3.158 2.124 4.696
GFI136N 20.125 0.000 2.212 1.564 3.130
CI 5 confidence interval.
aIPSS was defined in four different entities as published (for details, see
main text).
Supplementary Table E2. Cox survival regression adjusted for key
prognostic factorsa
Variable Wald c2 P value
Hazard
ratio
95.0% CI for
hazard ratio
Lower Upper
Age 4.761 0.029 1.010 1.001 1.019
Blast (% BM) 7.141 0.008 1.045 1.012 1.078
Male 0.518 0.472 1.111 0.834 1.479
IPSS 5.682 0.224
IPSS low 5.081 0.024 0.571 0.351 0.930
IPSS intermediate 1 2.561 0.110 0 .728 0.494 1.074
IPSS intermediate 2 0.205 0.651 0.909 0.603 1.371
IPSS high 0.088 0.767 1.105 0.570 2.144
Cytogenetic 12.264 0.007
Cytogenetic good 0.115 0.735 0.894 0.466 1.713
Cytogenetic
intermediate
1.089 0.297 0.686 0.339 1.392
Cytogenetic poor 1.278 0 .258 1.469 0.754 2.862
GFI136N 10.720 0.001 2.154 1.361 3.409
CI 5 confidence interval.
aCox survival regression adjusted for age, blast count, sex, IPSS, cytoge-
netic finding, and as a last step, presence of GFI136N (see main text for
more information).
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